Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

1-34. (**Cancelled**)

35. (**Currently amended**) A complex comprising a first peptide and a second peptide bound thereto, the first peptide comprising the V3 loop of gp120, and wherein the V3 loop is ~~bound~~ exposed or available and thereby bound to a binding region on the second peptide to form the complex, said second peptide comprising the binding region which region comprises at least residues 21-40 and 46-58 of the Tat protein set forth in SEQ ID NO 1, or at least said residues with a further point mutation whereby Cys 22 of Tat is replaced by Glycine to form a Tat22Cys22 mutant, said Tat protein ~~being capable of~~ binding a region on gp120 comprising residues 301-419 of a gp120 protein as set forth in SEQ ID NO. 2.

36. (**Previously amended**) A complex comprising a first peptide and a second peptide bound thereto, the first peptide comprising the V3 loop of gp120, and wherein the V3 loop is exposed or available and thereby bound to a binding region on the second peptide to form the complex, the binding region on the second peptide being derived from Tat and being recognisable by a monoclonal antibody directed against the CCR5 second extracellular loop.

37. (**Currently amended**) The complex of claim 35, wherein the binding region comprises at least residues 21-58 of Tat as set forth in SEQ ID NO 1, or a Tat22Cys22 mutant thereof capable of binding residues 301-419 of SEQ ID NO. 2.

38. (**Previously amended**) The complex of claim 35, prepared with native Tat.

39. (**Previously amended**) The complex of claim 35, wherein the peptide comprising the V3 loop comprises some or all of gp120 in addition to the V3 loop.

40. (**Previously amended**) The complex of claim 35, wherein the peptide comprising the V3 loop comprises the complete sequence of SEQ ID NO 2, or said sequence with a further point mutation whereby a residue corresponding to Cys22 of Tat in SEQ ID NO:1 is replaced by ~~g~~ ~~lycine~~ glycine and which is capable of binding a peptide consisting of residues 21-58 of SEQ ID NO 1.

41. (**Previously amended**) The complex of claim 35, wherein the peptide comprising the V3 loop consists of the V3 loop region of gp120.

42. (**Currently amended**) The complex of claim 35, wherein the peptide comprising the V3 loop comprises at least residues 301-419 of SEQ ID NO. 2, ~~or a fragment, variant or mutant thereof~~ capable of binding a peptide consisting of residues 21-58 of SEQ ID NO 1.

43. (**Previously amended**) The complex of claim 35, having all or part of gp160 as a component thereof, the gp160 comprising at least the V3 loop of gp120 and lacking at least the majority of the V2 loop of gp120.

44. (**Previously amended**) The complex of claim 35, having ΔV2Env as a component thereof.

45. (**Currently amended**) The complex of claim 35, wherein the peptide comprising the V3 loop comprises at least residues 301 to 419 of gp120 as shown in SEQ ID NO. 2.

46. (**Previously amended**) The complex of claim 35 comprising a gp120 protein and further comprising a molecule or substance capable of interacting with Env to expose a functional V3 loop.

47. (**Currently amended**) The complex of claim 46, wherein said molecule or substance is CD4 ~~or a fragment, mutant or variant thereof capable of interacting~~ and interacts with Env to expose a functional V3 loop.

48. (**Previously amended**) The complex of claim 35, further comprising a heparan sulphate.

49. (**Previously amended**) The complex of claim 35, further comprising a substance selected from the group consisting of integrins, basic fibroblast growth factor, CD26, VEGF receptors, and chemokine receptors.

50. (**Previously amended**) The complex of claim 35, wherein the binding region is contained within a fragment of Tat generatable by proteasomes of human cells on exposure to Tat, wherein the Tat fragment from the group consisting of fragments containing the cysteine, basic and RGD regions of Tat; fragments containing the cysteine and basic regions of Tat; fragments containing the basic and RGD region of Tat; and, fragments containing the basic region of Tat, alone.

51. (**Cancelled**)

52. (**Previously amended**) The complex of claim 35, wherein said peptides are cross-linked.

53. (**Withdrawn**) Use of the complex of claim 35 in an immunogenic composition for generating antibodies thereagainst.

54. (**Withdrawn**) The use of the immunogenic composition of claim 53 in a process to obtain a monoclonal cell line.

55. (**Withdrawn**) The use of claim 53, wherein the antibodies are selected such as not to recognise any of the epitopes of the group of native Tat, gp160, CD4 or gp120, CCR5, and the V3 loop region of gp120 also recognized by antibodies

generated by one of the group when used as immunogen in isolation or in a complex lacking Tat, but is only recognized as the complex of claim 35.

56. (**Withdrawn**) An antibody obtained by a process as defined in claim 52.

57-62. (**Cancelled**)

63. (**Previously amended**) A vehicle suitable for injection comprising the complex of claim 35.

64. (**Previously amended**) A kit comprising at least two separate preparations of the components of the complex of claim 35.

65. (**Withdrawn**) Use of the complex of claim 35 in therapy.

66. (**Withdrawn**) A method for the treatment or prophylaxis of a viral infection, whereby the infecting virus expresses a molecule capable of forming a ternary complex between said molecule, CD4 and CCR5, comprising administering the complex of claim 35 to patient in need thereof .

67. (**Withdrawn**) Use of the complex of claim 35 to establish whether a sample from a patient contains antibodies against said complex.

68. (**Previously presented**) A complex according to claim 35, wherein the second peptide comprises at least residues 21-60 of Tat (SEQ ID NO: 1) with a further point mutation whereby a residue corresponding to Cys 22 of Tat in SEQ ID NO: 1 is replaced by Glycine.

69. (**Currently amended**) A complex comprising a first peptide and a second peptide bound thereto,

the first peptide comprising the V3 loop of gp120, and wherein the V3 loop is exposed or available and thereby bound to a binding region on the second peptide to form the complex,

the second peptide comprising said binding region which region comprises at least residues 21-40 and 46-58 of Tat (SEQ ID NO 1), or at least said residues with a further point mutation whereby Cys 22 of Tat is replaced by Glycine to produce a Tat Cys22 mutant, said Tat Cys22 mutant being capable of binding a region on gp120 comprising residues 301-419 of gp120 (SEQ ID NO. 2);

wherein, the first peptide comprising the V3 loop is selected from the group consisting of:

- an isolated V3 loop region of gp120;

- a peptide consist of at least residues 301-419 of SEQ ID NO. 2, ~~or a fragment, variant or mutant thereof~~ capable of binding a peptide consisting of residues 21-58 of SEQ ID NO 1;

- gp160 comprising at least the V3 loop of gp120 and lacking at least the majority of the V2 loop of gp120;

- ΔV2Env; and

- the trimeric gp140 form of Env, retaining part of gp41 and lacks the V2 loop of Env .

70. (**Previously presented**) A complex comprising a first peptide and a second peptide bound thereto,

the first peptide comprising the V3 loop of gp120, and wherein the V3 loop is exposed or available and thereby bound to a binding region on the second peptide to form the complex,

the second peptide comprising said binding region which region comprises at least residues 21-40 and 46-58 of Tat (SEQ ID NO 1), or at least said residues with a further point mutation whereby Cys 22 of Tat is replaced by Glycine, said Tat Cys22 mutant being capable of binding a region on gp120 comprising residues 301-419 of gp120 (SEQ ID NO. 2);

wherein, the complex further comprising a molecule or substance capable of interacting with Env to expose a functional V3 loop or the peptides are cross-linked.

71. (**Currently amended**) A complex according to claim 70, wherein said molecule or substance is CD4 ~~or a fragment, mutant or variant thereof~~ capable of interacting with Env to expose a functional V3 loop.

72. (**Previously presented**) A complex according to claim 70, wherein the molecule or substance is a heparan sulphate.